{"disease":{"id":"normal-renal-function","name":"normal renal function"},"drugs":{"marketed":[{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with normal renal function.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03226327","title":"A Pilot Trial of Manlikang in Reducing Salt Intake and Blood Pressure Among Patients With Hypertension","phase":"NA","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT02431481","title":"Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02965040","title":"A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":false},{"nct_id":"NCT04656795","title":"PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Tanabe Pharma America, Inc.","has_results":false},{"nct_id":"NCT04699877","title":"A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}